Lexaria Bioscience Corp. (NASDAQ: LEXX) announced the extension of its Material Transfer Agreement (MTA) with a pharmaceutical company, referred to as PharmaCO, originally signed on August 30, 2024. The agreement has been extended through December 31, 2026, to allow time for PharmaCO to receive and review Lexaria's 2026 research and development results related to GLP-1 receptor agonists. This extension keeps the temporary exclusive license active and enables further strategic planning discussions involving PharmaCO's human clinical and business development teams.
The MTA was initially established to evaluate Lexaria's DehydraTECH™ technology in a preclinical setting. DehydraTECH is a patented oral drug delivery platform that enhances the bioavailability and reduces side effects of various drugs, including those targeting GLP-1 pathways. Over the past 12 months, Lexaria has made significant progress in its GLP-1 development program, with recently announced advances in three 2026 R&D studies: Human Study #7, Animal Study #1, and Animal Study #2. All studies are within the GLP-1 sector and are designed to provide comprehensive evidence to support further collaboration and potential licensing of the technology. The studies are fully funded with existing corporate resources, and results are expected during the third and fourth quarters of 2026.
The extension of the MTA underscores the potential value of Lexaria's drug delivery technology in the competitive GLP-1 market, which includes blockbuster drugs for diabetes and obesity. By facilitating deeper evaluation and potential partnership, this agreement could accelerate the development of improved oral GLP-1 therapies. For more information on Lexaria and its technology, visit www.lexariabioscience.com.
Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 65 patents granted and additional patents pending worldwide. The company's DehydraTECH platform has repeatedly demonstrated the ability to increase bio-absorption, reduce side effects, and deliver some drugs more effectively across the blood-brain barrier. This extension allows both parties to continue their collaboration and contemplate additional strategic discussions that could lead to licensing agreements or further joint development.
